Details of the Drug Combinations

General Information of This Drug (ID: DM5FLTY)

Drug Name

Risedronate DM5FLTY

Synonyms

Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,; Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID

Indication

Disease Entry	ICD 11	Status	REF
Bone Paget disease	N.A.	Approved	[1]
Osteoporosis	FB83.0	Approved	[1]
Paget's disease	FB85	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Bone Density Conservation Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Risedronate + Panobinostat	DC3I5HK	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Risedronate + Marizomib	DCZMW6Z	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Risedronate + Anastrozole	DC1T71L	Anastrozole	Breast Cancer	[4]
Risedronate + Testosterone	DCIABDR	Testosterone	Anorexia Nervosa	[5]
Risedronate + Teriparatide	DCLN5KU	Teriparatide	Osteoporosis	[6]
------------------------------------------------------------------------------------

References

1	Risedronate FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3176).
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	ClinicalTrials.gov (NCT00082277) Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
5	ClinicalTrials.gov (NCT00089843) Bone Loss in Women With Anorexia Nervosa
6	ClinicalTrials.gov (NCT01611571) Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis